Opexa Therapeutics, Inc. (OPXA) said Monday that it has appointed Karthik Radhakrishnan as Chief Financial Officer.
Radhakrishnan joins Opexa with over 10 years of healthcare capital markets experience and most recently was a Vice President at ING Investment Management in New York. He replaces David Jorden, Opexa's Acting CFO, who will continue to serve as a Director of the company.
Opexa alos said it has appointed Kenny Frazier as Vice President of Clinical Development and Regulatory Affairs and Maryann Murray as Clinical Development Manager. Frazier was previously at Lexicon Pharmaceuticals, where he was a Senior Director of Clinical Operations, while Ms. Murray was previously at The University of Texas Health Science Center as a Research Coordinator.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.